Psychiatry Medical News about Cannabis

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Pharmacotherapy for Cannabis Dependence: How Close Are We
CNS Drugs, 06/29/09

Vandrey R et al. - Results from controlled laboratory studies and small open-label clinical studies indicate that buspirone, dronabinol, fluoxetine, lithium and lofexidine may have therapeutic benefit for those seeking treatment for cannabis-related problems. However, controlled clinical trials have not been conducted and are needed to both confirm the potential clinical efficacy of these medications and to validate the laboratory models being used to study candidate medications.

<< Previous
Protein Kinase C Inhibitors: Rationale for Use and Potential in...

Next >>
Cognitive Effects of Second-Generation Antipsychotics: Current...

New UK study suggests minimal relationship between cannabis and schizophrenia or psychosis
EurekAlert, 10/23/09 Relevance Score: 91%

If cannabis caused schizophrenia how many cannabis users may need to be prevented in order to prevent one case of schizophrenia? England and Wales calculations
Addiction, 10/19/09 Relevance Score: 91%

Adverse health effects of non-medical cannabis use
The Lancet, 10/19/09 Relevance Score: 88%

Cannabis and First-Episode Psychosis: Different Long-term Outcomes Depending on Continued or Discontinued Use
Schizophrenia Bulletin, 11/16/09 Relevance Score: 87%

Intrauterine Cannabis Exposure Affects Fetal Growth Trajectories: The Generation R Study
Journal of the American Academy of Child and Adolescent Psychiatry, 10/29/09 Relevance Score: 87%